- Home
- RYN vs HAE Comparison
RYN vs HAE Comparison
Compare RYN & HAE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RYN
- HAE
- Stock Information
- Founded
- RYN 1926
- HAE 1971
- Country
- RYN United States
- HAE United States
- Employees
- RYN N/A
- HAE N/A
- Industry
- RYN Real Estate Investment Trusts
- HAE Medical/Dental Instruments
- Sector
- RYN Real Estate
- HAE Health Care
- Exchange
- RYN Nasdaq
- HAE Nasdaq
- Market Cap
- RYN 4.5B
- HAE 3.6B
- IPO Year
- RYN N/A
- HAE 1991
- Fundamental
- Price
- RYN $25.59
- HAE $69.02
- Analyst Decision
- RYN Hold
- HAE Strong Buy
- Analyst Count
- RYN 4
- HAE 9
- Target Price
- RYN $31.00
- HAE $108.78
- AVG Volume (30 Days)
- RYN 761.9K
- HAE 710.9K
- Earning Date
- RYN 02-05-2025
- HAE 02-06-2025
- Dividend Yield
- RYN 4.44%
- HAE N/A
- EPS Growth
- RYN 98.46
- HAE N/A
- EPS
- RYN 1.07
- HAE 2.41
- Revenue
- RYN $1,004,107,000.00
- HAE $1,361,223,000.00
- Revenue This Year
- RYN N/A
- HAE $7.56
- Revenue Next Year
- RYN N/A
- HAE $3.13
- P/E Ratio
- RYN $24.10
- HAE $27.45
- Revenue Growth
- RYN 20.26
- HAE 9.84
- 52 Week Low
- RYN $24.88
- HAE $65.73
- 52 Week High
- RYN $35.29
- HAE $97.97
- Technical
- Relative Strength Index (RSI)
- RYN 38.05
- HAE 37.93
- Support Level
- RYN $25.82
- HAE $65.73
- Resistance Level
- RYN $26.50
- HAE $71.11
- Average True Range (ATR)
- RYN 0.49
- HAE 3.24
- MACD
- RYN 0.06
- HAE -0.40
- Stochastic Oscillator
- RYN 4.03
- HAE 19.43
About RYN Rayonier Inc. REIT
Rayonier owns and manages over 2 million acres of timberland in the United States. It is one the largest private landowners in North America. The firm also owns timberland in New Zealand. Rayonier is structured as a real estate investment trust and is not required to pay federal income taxes on earnings generated by timber harvest activities.
About HAE Haemonetics Corporation
Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company places primary emphasis on its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.